Audio Journal of Oncology, December 10th, 2007
Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
ANTON HAGENBEEK, University Medical Centre Utrecht
REFERENCE: ABSTRACT 643, ASH 2007
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.
